SCHEMBL4764752

SCHEMBL4764752

COc1cc(C2=NC(=O)c3ccccc3C2)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.46
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
FAAH O00519 1/20 0.41
GRM5 P41594 5/20 0.38
GRM1 Q13255 3/20 0.38
BUB1 O43683 1/20 0.37
PDCD1 Q15116 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
CYP19A1 P11511 1/20 0.37
LRRK2 Q5S007 1/20 0.36
DYRK1A Q13627 1/20 0.36
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767059 0.83 MAPK14 (0.37) PDE3BPDE3AGRM5CYP19A1
SCHEMBL4766311 0.79 MEN1 (0.48) IDO1PDE3BPDE3APDCD1CD274
SCHEMBL4771354 0.79 ABL1 (0.44) MEN1USP2TP53MAPTTSHR
SCHEMBL4768931 0.77 CCR1 (0.47) FAAHMEN1TP53MAPTTSHR
SCHEMBL4769027 0.77 NPC1 (0.46) PDCD1CD274MEN1TP53MAPT
SCHEMBL4763654 0.74 ALDH1A1 (0.47) PDCD1CD274MEN1USP2MAPT
SCHEMBL4774181 0.73 MEN1 (0.48) MEN1MAPTKMT2ASMN1; SMN2
SCHEMBL4772003 0.70 PTPN1 (0.45) MEN1TP53MAPTTSHRKMT2A
SCHEMBL4774292 0.70 HDAC4 (0.49) MEN1TP53MAPTTSHRKMT2A
SCHEMBL744054 0.70 IDO1 (0.50) IDO1FAAHPDCD1CD274CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 IDO1 1075/4885PDE3B 498/4885PDE3A 276/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 IDO1 216/4885PDE3B 251/4885PDE3A 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.